Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

By M. Norelli, B. Camisa, G. Barbiera, Laura Falcone, Ayurzana Purevdorj, M. Genua, F. Sanvito, M. Ponzoni, C. Doglioni, P. Cristofori and 7 more. Nature Medicine, 2018

1,261 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/b6c573adcfabe8737d243eccb33b460ae1088fee

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

T. Hirano

In Oncology

Citations in the corpus

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 (2020, positive): “Should this be true, drugs such as tocilizumab and anakinra may prove to be beneficial for treatment of COVID-19 (Norelli et al., 2018).”
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. (2019, background): “This perhaps reflects induction of an (ultimately ineffective) feedback mechanism in patients with neurotoxicity, and suggests that augmenting IL-1 blockade with the recombinant IL-1RA anakinra may have therapeutic benefit, as demonstrated in pre-clinical models (33, 34).”
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality (2020, neutral): “[5] Norelli M , Camisa B , Barbiera G , Falcone L , Purevdorj A , Genua M , et al.”
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions (2020, positive): “Inhibitors of IL-6 or its receptor have been successful in treating other cytokine storm syndromes, such as reHLH associated with adultonset Still’s disease [120], or CRS secondary to CAR T cell therapies [28,121].”
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy (2020, background): “Cytokine-release syndrome is thought to be mediated mainly through the release of IL-1, and targeted anti-IL-1 therapy might reduce this side effect.(59) Currently, projects using gene-editing tools, such as CRISPR/ Cas9 to edit out genes that increase the risk of side effects, are under investigati”
Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, background): “Similarly, preclinical evidence implicates IL-1 released by monocytes and/or macrophages in CAR T cell-associated CRS and ICANS 71,72 .”
IL-6 in inflammation, autoimmunity and cancer (2020, background): “IL-1 and IL-6 are involved in the lethal cytokine storm sometimes seen in CAR-T treatment (353, 354).”
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, background): “Multiple groups have demonstrated the successful use of the IL-1 antagonist anakinra to ameliorate CRS in mouse models [72,73].”